Short Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABS) Rises By 38.3%

SAB Biotherapeutics, Inc. (NASDAQ:SABSGet Free Report) was the recipient of a large increase in short interest in March. As of March 31st, there was short interest totalling 28,900 shares, an increase of 38.3% from the March 15th total of 20,900 shares. Based on an average trading volume of 17,400 shares, the short-interest ratio is currently 1.7 days. Approximately 0.4% of the shares of the company are short sold.

Institutional Investors Weigh In On SAB Biotherapeutics

A number of large investors have recently bought and sold shares of SABS. Vanguard Group Inc. grew its position in SAB Biotherapeutics by 5.6% during the 1st quarter. Vanguard Group Inc. now owns 721,151 shares of the company’s stock worth $2,712,000 after acquiring an additional 38,179 shares during the last quarter. State Street Corp grew its position in SAB Biotherapeutics by 244.2% during the 1st quarter. State Street Corp now owns 42,341 shares of the company’s stock worth $159,000 after acquiring an additional 30,041 shares during the last quarter. Millennium Management LLC bought a new stake in SAB Biotherapeutics during the 2nd quarter worth approximately $93,000. Citadel Advisors LLC bought a new stake in SAB Biotherapeutics during the 3rd quarter worth approximately $28,000. Finally, HighTower Advisors LLC bought a new stake in SAB Biotherapeutics during the 4th quarter worth approximately $44,000. 7.82% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

SABS has been the subject of a number of recent research reports. HC Wainwright dropped their target price on SAB Biotherapeutics from $10.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, April 2nd. Chardan Capital increased their target price on SAB Biotherapeutics from $3.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, April 2nd.

Check Out Our Latest Stock Analysis on SABS

SAB Biotherapeutics Price Performance

Shares of SABS traded up $0.17 during mid-day trading on Friday, reaching $4.68. The company had a trading volume of 3,497 shares, compared to its average volume of 11,938. SAB Biotherapeutics has a twelve month low of $4.00 and a twelve month high of $14.50. The company has a current ratio of 5.45, a quick ratio of 5.45 and a debt-to-equity ratio of 0.06. The company’s 50-day moving average is $5.00 and its 200-day moving average is $3.06.

SAB Biotherapeutics Company Profile

(Get Free Report)

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.

Featured Articles

Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.